

1 **Safety of anti-thrombotic therapy in acute aortic dissection; single**
2 **center, observational study**

3
4 Kensuke Hori, MD¹; Nagisa Morikawa MD, PhD¹; Eiki Tayama, MD, PhD²; Yoshihiro
5 Fukumoto, MD, PhD¹

6
7 1) Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume
8 University School of Medicine

9 2) Department of Surgery, Kurume University School of Medicine

10
11 Short title: Aortic dissection and anti-thrombosis

12 Total word count: 2,514 words of text with 4 figures and 10 tables

13
14 Address for correspondence:

15 Yoshihiro Fukumoto MD, PhD

16 Professor and Chairman

17 Division of Cardiovascular Medicine, Department of Internal Medicine

18 Kurume University School of Medicine

19 67 Asahi-machi, Kurume, 830- 0011, Japan

20 (Tel)+81-942-31-7562

21 (Fax)+81-942-33-6509

22 (EM) fukumoto_yoshihiro@med.kurume-u.ac.jp

23

24

25 **ABSTRACT**

26 **Background**

27 Acute aortic dissection occurs due to a primary tear in aortic intima, with blood from
28 aortic lumen penetrating into diseased media, in which anti-thrombotic therapies may be
29 harmful. We examined the prognosis in patients, who had already taken antithrombotic
30 therapies at the onset of acute aortic dissection, and the safety to administer anti-
31 thrombotic drugs in acute phase during hospitalization.

32 **Methods and Results**

33 We retrospectively enrolled 685 patients with acute aortic dissection (type A/B: 454/231),
34 who were transferred to Kurume University Hospital from 2004 to 2020. In both type A
35 and B, there were no significant differences in in-hospital mortality between with and
36 without antithrombotic therapies at the onset. Patients, who survived more than a day and
37 administered anti-thrombotic drugs during hospitalization, had significantly lower in-
38 hospital mortality than those who had no anti-thrombosis in acute phase in type A, while
39 there was no significant difference in in-hospital mortality between the 2 groups in type
40 B.

41 **Conclusions**

42 We demonstrated that anti-thrombotic drugs did not worsen the prognosis in patients with

43 acute aortic dissection, indicating that we should not hesitate anti-thrombotic drugs if

44 indicated.

45

46 **Key Words:** acute aortic dissection; anti-thrombosis; mortality; anti-coagulant; anti-

47 platelet.

48

49

Introduction

50

51 Acute aortic dissection has poor prognosis,[1, 2] frequently resulting in sudden
52 cardiac death. There are several classifications in acute aortic dissection, in which
53 Stanford type A is classified as “all dissections involving the ascending aorta, regardless
54 of the site of origin”, and Stanford type B is as “all dissections not involving the ascending
55 aorta”.[3] Historically, the mortality of Stanford type A approaches 1% per hour,[4] and
56 Stanford type B had 10 to 25% of mortality at 30 days.[3] Although diagnostic modalities
57 and therapeutic strategies including surgical and endovascular treatment have recently
58 advanced, mortality rate remains still high.[5]

59 Accumulated evidence has demonstrated that the inflammation plays a central
60 role in the pathogenesis of acute aortic dissection.[6-8] Acute aortic dissection occurs due
61 to a primary tear in aortic intima, with blood from aortic lumen penetrating into diseased
62 media.[8] As initial medical therapy, blood pressure, heart rate, and pain should be
63 initially treated to optimize patient stabilization during interhospital transfer and surgical
64 triage.[9] In such situation, data regarding anti-thrombotic therapies remains scant, which
65 seems to be harmful. However, acute aortic dissection suddenly occurs even in patients,
66 who have already taken anti-thrombotic therapies, in the clinical settings. Further, anti-

67 thrombotic drugs are occasionally required for several reasons, such as atrial fibrillation,
68 during the hospitalization of acute aortic dissection.

69 Currently, it has not been fully elucidated if anti-thrombotic drugs do harm in
70 patients with acute aortic dissection. Therefore, the present study aimed to examine the
71 impact of anti-thrombotic therapies at the onset of acute aortic dissection and the safety
72 of anti-thrombotic agents use during hospitalization in acute phase of acute aortic
73 dissection.

74

75

76

Methods

77 Study Design

78 This study was a retrospective observational study using the database of Coronary Care
79 Unit / Cardiovascular Medicine, Kurume University Hospital. We enrolled patients with
80 acute aortic dissection, who were transferred to Coronary Care Unit / Cardiovascular
81 Medicine, Kurume University Hospital from January 2004 to December 2020. The
82 present study was approved by the institutional review board at Kurume University
83 (21280). The informed consent was waived due to the retrospective nature and opt-out
84 was used in the study.

85

86 Data Collection

87 Baseline demographic data, when patients arrive at the hospital, were collected based on
88 the medical records, including age, sex, height, body weight, waist, medications including
89 anti-thrombosis (warfarin, direct oral anti-coagulants (DOAC), aspirin, clopidogrel),
90 traditional risk factors (hypertension, glucose intolerance/diabetes mellitus and
91 dyslipidemia), blood pressure (BP), pulse rate, heart rate, and comorbidities (coronary
92 artery disease, hypertensive heart disease, cardiomyopathy, valvular heart diseases, and
93 congenital heart diseases). Coronary artery diseases included chronic stable angina,

94 asymptomatic myocardial ischemia, acute coronary syndrome, prior myocardial
95 infarction, prior coronary revascularization, coronary spastic angina, and nonobstructive
96 coronary atherosclerosis. Venous thromboembolism included pulmonary
97 thromboembolism and deep vein thrombosis. Left ventricular (LV) dysfunction was
98 defined as LV ejection fraction <50%. “Genetic and others” includes Marfan syndrome,
99 Loeys-Dietz syndrome, and Behçet's disease. Other clinical diagnosis and medication
100 data were obtained from medical records. All patients were ascertained smoking and
101 drinking habits by a questionnaire. Alcohol intake and smoking were classified as current
102 habitual use or not. Major bleeding was defined as fatal bleeding and/or symptomatic
103 bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular,
104 retroperitoneal, intraarticular or pericardial, or intramuscular with compartment
105 syndrome, referred to International Society on Thrombosis and Haemostasis.[10]
106 Infarction included myocardial, cerebral, and peripheral, including abdominal and limb,
107 arteries infarction. Data of death during hospitalization were collected based on medical
108 records. All cardiovascular diseases were diagnosed by expert cardiologists.

109

110 **Blood sampling**

111 Blood samples were obtained from the antecubital vein and measured at a commercially

112 available laboratory in Kurume University Hospital. Estimated glomerular filtration rate
113 (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study
114 equation modified with a Japanese coefficient[11]: $eGFR (ml \cdot min^{-1} \cdot 1.73 m^{-2}) = 194$
115 $\times age^{-0.287} \times serum \text{ creatinine}^{-1.094}$ (if female $\times 0.739$).

116

117 **Outcome**

118 Primary outcome was defined as death from any cause during hospitalization, all of
119 which were identified in the medical records.

120

121 **Statistical Analysis**

122 Data were presented mean \pm standard error (SE) and compared between groups using
123 two-sided *t*-tests. Categorical variables were presented as frequency and percent
124 proportions and compared between groups using chi-square tests. Survival curves of
125 death from all causes were estimated by the Kaplan-Meier method and compared using
126 the log-rank test. Cox proportional hazards models were used to estimate hazard ratios
127 (HRs) and 95% confidence intervals (CIs) for all-cause mortality. Next, we adjusted the
128 models for age and sex. Statistical significance was defined as $p < 0.05$. All statistical
129 analyses were performed using the SAS system (Release 9.4, SAS Institute, Cary, NC,

130 USA).

131

132 **Results**

133

134 **Transferred patients**

135 A total of 685 patients with acute aortic dissection were transferred to our hospital from
136 January 2004 to December 2020 (**Figure 1**). There were 454 type A and 231 type B
137 patients. In type A, 70 patients were treated by antithrombosis drugs on admission,
138 including 24 with anti-coagulants, 39 anti-platelet drugs, and 7 both (**Figure 1**).
139 Characteristics of transferred patients at baseline were shown in **Table 1**.

140

141 **Table 1. Clinical characteristics of transferred acute aortic dissection patients**

	Stanford type A (n=454)			Stanford type B (n=231)		
	yes	no	P value	yes	no	P value
Anti-thrombotic therapy (at the onset)	(n=70)	(n=384)		(n=38)	(n=193)	
Hospital stay (days)	38.3±35.6	28.9 ± 22.1	0.04	28.7 ± 28.7	26.1 ± 20.5	0.59
Age (years old)	74.8±8.9	68.2 ± 12.2	<0.01	69.8 ± 15.0	66.0± 11.8	0.14
Sex (male)	42 (60.0%)	183 (47.6%)	0.06	21 (55.3%)	137 (71.0%)	0.06
Surgical/endovascular treatment	59 (84.3%)	314 (81.8%)	0.61	3 (7.9%)	30 (15.5%)	0.22
Medical history						
A Fib	22 (31.4%)	13 (3.4%)	<0.01	9 (23.7%)	2 (1.0%)	<0.01
CAD	14 (20.0%)	13 (3.4%)	<0.01	8 (21.1%)	3 (1.6%)	<0.01
Other CVD	27 (38.6%)	36 (9.7%)	<0.01	12 (31.6%)	19 (10.0%)	<0.01
PAD	19 (27.1%)	40 (10.8%)	<0.01	14 (36.8%)	36 (18.7%)	0.01

VTE	1 (1.4%)	1 (0.3%)	0.18	0 (0.0%)	0 (0.0%)	
HT	66 (94.3%)	320 (86.5%)	0.07	37 (97.4%)	181 (94.8%)	0.49
DM	7 (10.0%)	26 (7.1%)	0.39	7 (18.9%)	24 (12.6%)	0.3
DLp	18 (25.7%)	78 (21.1%)	0.4	19 (50.0%)	38 (19.9%)	<0.01
Genetic and others	1 (1.4%)	8 (2.1%)	0.69	4 (10.5%)	4 (2.1%)	<0.01
Smoking	30 (44.8%)	133 (36.7%)	0.21	20 (54.1%)	127 (67.2%)	0.13
Alcohol	28 (41.8%)	109 (30.2%)	0.06	12 (32.4%)	83 (43.9%)	0.2
Surgical history						
post-AVR	6 (8.6%)	2 (0.5%)	<0.01	7 (18.4%)	0 (0.0%)	<0.01
post-MVR	0 (0.0%)	0 (0.0%)		1 (2.6%)	0 (0.0%)	0.02
CABG	2 (2.9%)	1 (0.3%)	0.02	2 (5.3%)	0 (0.0%)	<0.01
Intervention to aortic						
aneurysm and/or dissection	11 (15.7%)	14 (3.8%)	<0.01	15 (39.5%)	13 (6.8%)	<0.01
Complication						
Major bleeding	5 (7.1%)	25 (7.0%)	0.96	1 (2.6%)	7 (3.6%)	0.75
Infarctoin by aorite dissection	18 (25.7%)	78 (21.7%)	0.46	0 (0%)	20 (10.4%)	0.04
Paroxymal A Fib	19 (27.1%)	93 (25.9%)	0.83	2 (5.3%)	8 (4.1%)	0.77
Medication on admission						
RAAS inhibitor	31(45.6%)	93 (29.1%)	<0.01	22 (57.9%)	52 (28.1%)	<0.01
CCB	29 (42.7%)	97 (30.3%)	0.05	16 (42.1%)	51 (27.6%)	0.08
β-blocker	26 (38.2%)	31 (9.7%)	<0.01	12 (31.6%)	29 (15.7%)	0.02
diuretics	9 (13.2%)	18 (5.6%)	0.03	2 (5.3%)	8 (4.3%)	0.8
α-blocker	1 (1.5%)	9 (2.8%)	0.53	0 (0%)	7 (3.8%)	0.22
warfarin	25 (35.7%)	0 (0.0%)		13 (34.2%)	0 (0.0%)	
DOAC	6 (8.6%)	0 (0.0%)		3 (7.9%)	0 (0.0%)	
aspirin	27 (38.6%)	0 (0.0%)		20 (52.6%)	0 (0.0%)	
clopidogrel	12 (17.1%)	0 (0.0%)		5 (13.2%)	0 (0.0%)	
cilostazol	8 (11.4%)	0 (0.0%)		4 (10.5%)	0 (0.0%)	

prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	
Discharge medicine						
RAAS inhibitor	34 (57.6%)	199 (64.0%)	0.35	23 (62.2%)	149 (84.7%)	<0.01
CCB	26 (44.1%)	162 (52.1%)	0.26	28 (75.7%)	163 (92.6%)	<0.01
β-blocker	46 (78.0%)	248 (79.7%)	0.76	33 (89.2%)	158 (89.8%)	0.92
diuretics	21 (35.6%)	103 (33.1%)	0.71	8 (21.6%)	47 (26.7%)	0.91
α-blocker	2 (3.4%)	11 (3.5%)	0.96	2 (5.4%)	14 (8.0%)	0.59
warfarin	17 (28.3%)	59 (18.9%)	0.09	8 (21.6%)	2 (1.1%)	<0.01
DOAC	6 (10.0%)	15 (4.8%)	0.11	3 (8.1%)	2 (1.1%)	0.01
aspirin	24 (40.0%)	76 (24.3%)	0.01	12 (32.4%)	8 (4.5%)	<0.01
clopidogrel	5 (8.3%)	6 (1.9%)	<0.01	5 (13.5%)	0 (0.0%)	<0.01
cilostazol	5 (8.3%)	1 (0.3%)	<0.01	1 (2.7%)	0 (0.0%)	0.03
prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	

Data are mean ± SE, or mean (%), BP; blood pressure, eGFR; estimated glomerular filtration rate, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp; dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant.

Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease.

142

143 In type A, patients, who were already treated by anti-thrombosis, had significantly older
 144 age, higher prevalence of previous history of atrial fibrillation, cardiovascular diseases,
 145 coronary artery bypass graft, and aortic valve replacement, and renin-angiotensin-
 146 aldosterone system (RAAS) inhibitors (angiotensin converting enzyme inhibitors and/or
 147 angiotensin II receptor blockers), calcium channel blocker, and β-blocker use. Among
 148 them, 10 patients (14.3%) died during the hospitalization (**Figure 1**).

149

150 **Figure 1. Enrollment of transferred patients with acute aortic dissection**

151 Among 685 transferred patients, 15% in 454 type A and 16% in 231 type B patients had
152 already taken anti-thrombotic drugs.

153

154 In the remaining 384 patients with type A, who have not treated by anti-
155 thrombosis drugs, 63 patients (16.4%) died during the hospitalization (**Figure 1**). In
156 Kaplan-Meier curve, patients treated by antithrombosis drugs on admission did not show
157 worse prognosis compared with no anti-thrombosis drug group in type A (**Figure 2A**).

158

159 **Figure 2. Kaplan-Meier curves of transferred patients with acute aortic dissection**

160 There were no significant differences in survival rate between with and without anti-
161 thrombotic drugs on admission in both type A (panel A) and B (panel B).

162

163 In type B, 38 patients were treated by antithrombosis drugs on admission,
164 including 11 with anti-coagulants, 22 anti-platelet drugs, and 5 both, who had
165 significantly higher prevalence of previous history of atrial fibrillation, coronary artery
166 disease, dyslipidemia, aortic valve replacement, and coronary artery bypass graft, and

167 RAAS inhibitors use (**Figure 1, Table 1**). Among them, 1 patient (2.6%) died during the
168 hospitalization. In the remaining 193 patients with type B, who have not treated by anti-
169 thrombosis drugs, 14 patients (7.3%) died during the hospitalization. Kaplan-Meier curve
170 indicated the comparable prognosis between the 2 groups of type B (**Figure 2B**).

171

172 **Hospitalized patients**

173 A total of 650 patients with acute aortic dissection survived for more than a day and
174 hospitalized (**Figure 3**). There were 424 type A and 226 type B patients. In type A, 182
175 patients were treated by antithrombosis drugs during hospitalization, including 64 with
176 anti-coagulants, 73 anti-platelet drugs, and 45 both. Characteristics of hospitalized
177 patients at baseline were shown in **Table 2**. Type A patients had significantly higher
178 prevalence of atrial fibrillation and genetic and other aortic diseases, including Marfan
179 syndrome, Loeys-Dietz syndrome, and Behçet's disease (**Table 2**).

180

181 **Table 2. Clinical characteristics of hospitalized acute aortic dissection**

	Stanford type A (n=424)			Stanford type B (n=226)		
Anti-thrombotic therapy (at the onset)	yes (n=182)	no (n=242)	P value	yes (n=42)	no (n=184)	P value
Hospital stay (days)	36.9±24.5	29.1± 23.8	<0.01	35.6±30.8	25.7 ±20.0	0.01

Age (years old)	69.9±11.3	68.3± 12.3	0.17	67.8±15.0	66.4 ± 11.8	0.51
Sex (male)	91 (50.0%)	120 (49.6%)	0.9	23 (54.8%)	131 (71.2%)	0.04
Surgical/endovascular treatment	177 (97.3%)	194 (80.2%)	<0.01	6 (14.3)	25 (13.6)	0.91
Medical history						
A Fib	25 (13.7%)	9 (3.7%)	<0.01	6 (14.3%)	4 (2.2%)	<0.01
CAD	13 (7.1%)	11 (4.6%)	0.27	7 (16.7%)	4 (2.2%)	<0.01
Other CVD	34 (18.7%)	27 (11.3%)	0.03	9 (21.4%)	20 (10.9%)	0.06
PAD	23 (12.6%)	32 (13.5%)	0.81	12 (28.6%)	37 (20.1%)	0.49
VTE	2 (1.1%)	0 (0.0%)	0.11	0 (0.0%)	0 (0.0%)	
HT	159 (87.4%)	213 (90.3%)	0.35	40 (95.2%)	175 (95.1%)	0.97
DM	17 (9.3%)	15 (6.4%)	0.26	7 (17.1%)	23 (12.5%)	0.44
DLp	37 (20.3%)	55 (23.4%)	0.45	16 (38.1%)	39 (21.2%)	0.02
Genetic and others	7 (3.8%)	1 (0.4%)	0.01	4 (9.5%)	4 (2.2%)	0.02
Smoking	65 (35.7%)	95 (41.1%)	0.26	23 (56.1%)	122 (67.0%)	0.18
Alcohol	60 (33.0%)	75 (32.6%)	0.94	13 (31.7%)	81 (44.5%)	0.13
Surgical history						
post-AVR	5 (2.7%)	2 (0.8%)	0.13	6 (14.3%)	1 (0.5%)	<0.01
post-MVR	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.5%)	0.63
CABG	2 (1.1%)	1 (0.4%)	0.42	2 (4.8%)	0 (0.0%)	<0.01
Intervention to aortic aneurysm and/or dissection	13 (7.1%)	10 (4.2%)	0.2	10 (24.4%)	17 (9.2%)	<0.01
Complication						
Major bleeding	8 (4.5%)	18 (7.8%)	0.17	0 (0%)	6 (3.3%)	0.24
Infarctoin by aortic dissection	45 (25.1%)	41 (17.8%)	0.07	4 (9.5%)	16 (8.7%)	0.86
Paroxymal A Fib	77 (43.0%)	35 (15.2%)	<0.01	3 (7.1%)	7 (3.8%)	0.34
Medication on admission						
RAAS inhibitor	58 (35.4%)	61 (29.3%)	0.22	18 (42.9%)	56 (31.3%)	0.15

CCB	55 (33.5%)	66 (31.7%)	0.71	12 (28.6%)	54 (30.2%)	0.84
β-blocker	30 (18.3%)	24 (11.5%)	0.07	8 (19.0%)	32 (17.9%)	0.86
diuretics	15 (9.2%)	10 (4.8%)	0.09	1 (2.4%)	7 (3.9%)	0.63
α-blocker	2 (1.2%)	7 (3.4%)	0.18	0 (0%)	7 (3.9%)	0.19
warfarin	20 (12.1%)	4 (1.9%)	<0.01	10(23.8%)	2 (1.1%)	<0.01
DOAC	5 (3.0%)	1 (0.5%)	0.05	3 (7.1%)	0 (0.0%)	<0.01
aspirin	15 (9.0%)	9 (4.3%)	0.06	15 (35.7%)	5 (2.8%)	<0.01
clopidogrel	9 (5.4%)	3 (1.4%)	0.03	5 (11.9%)	0 (0%)	<0.01
cilostazol	4 (2.4%)	4 (1.9%)	0.74	3 (7.1%)	1 (0.5%)	<0.01
prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	
Discharge medicine						
RAAS inhibitor	107 (61.5%)	126 (64.3%)	0.58	28 (68.3%)	144 (83.7%)	0.02
CCB	75 (43.1%)	113 (57.7%)	<0.01	31 (75.6%)	160 (93.0%)	<0.01
β-blocker	146 (83.9%)	148 (75.5%)	0.046	35 (85.4%)	156 (90.7%)	0.31
diuretics	54 (31.0%)	70 (35.7%)	0.34	11 (26.8%)	44 (25.6%)	0.87
α-blocker	5 (2.9%)	8 (4.1%)	0.53	3 (7.3%)	13 (7.6%)	0.96
warfarin	76 (42.7%)	0 (0.0%)	<0.01	10 (24.4%)	0 (0.0%)	<0.01
DOAC	21 (11.8%)	0 (0.0%)	<0.01	5 (12.2%)	0 (0.0%)	<0.01
aspirin	100 (56.2%)	0 (0.0%)	<0.01	20 (48.8%)	0 (0.0%)	<0.01
clopidogrel	11 (6.2%)	0 (0.0%)	<0.01	5 (12.2%)	0 (0.0%)	<0.01
cilostazol	6 (3.4%)	0 (0.0%)	<0.01	1 (2.4%)	0 (0.0%)	0.04
prasugrel	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	

Data are mean ± SE, or mean (%), BP; blood pressure, eGFR; estimated glomerular filtration rate, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant.

Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease.

183 Among them, 4 patients (2.2%) died during hospitalization, and 178 (97.8%
184 were discharged (**Figure 3**). In the remaining 242 patients with type A, who have not
185 been treated by anti-thrombosis drugs, 39 patients (16.1%) died and 203 (83.9%) were
186 discharged (**Figure 3**). Kaplan-Meier curve showed the significantly better prognosis in
187 patients treated by antithrombosis drugs in type A (**Figure 4A**).

188

189 **Figure 3. Enrollment of hospitalized patients with acute aortic dissection**

190 Among 650 hospitalized patients, 43% in 424 type A and 19% in 225 type B patients
191 were treated by anti-thrombotic drugs during hospitalization.

192

193 **Figure 4. Kapan-Meier curves of hospitalized patients with acute aortic dissection**

194 Survival rate was significantly better in anti-thrombotic drug group than the other in type
195 A (panel A), while there was no significant difference between with and without anti-
196 thrombotic drugs during hospitalization in type B (panel B).

197

198 In 226 type B patients, 42 patients were treated by antithrombosis drugs,
199 including 15 with anti-coagulants, 26 anti-platelet drugs, and 1 both (**Figure 3**), who had
200 significantly higher prevalence of atrial fibrillation, coronary artery diseases, aortic valve

201 replacement, and coronary artery bypass graft (**Table 2**). Among them, 1 patient (2.4%)
202 died, and 41 were discharged. In the remaining 184 type B patients, who have not treated
203 by anti-thrombosis drugs, 9 patients (4.9%) died during hospitalization (**Figure 3**). In
204 Kaplan-Meier curve, there were no significant difference in prognosis in type B (**Figure**
205 **4B**).

206

207 **Cox proportional hazards regression analysis of all-cause death in TRANSFERRED**
208 **patients in type A**

209 In the Cox proportional hazards regression analysis of all-cause death, systolic blood
210 pressure, eGFR, history of hypertension, smoking habit, alcohol intake, complication of
211 surgical procedures, and use of α -blocker were significantly associated with all-cause
212 death (**Table 3**). In this analysis, the use of anti-thrombosis (warfarin, DOAC, aspirin,
213 clopidogrel) was not the predictor of all cause death (**Table 3**).

214

215 **Table 3. Cox proportional hazard model in transferred acute aortic dissection**
216 **patients (type A)**

	β	SE	p-value
Age	0.01	0.01	0.23
Sex	-0.02	0.23	0.94
Systolic BP	-0.02	<0.01	<0.01

	Diastolic BP	-0.01	0.008	0.19
	Heart rate	0.011	0.006	0.05
	eGFR	-0.028	0.006	<0.01
Past history				
	A Fib	-1.05	0.72	0.15
	CAD	0.76	0.4	0.06
	Other CVD	0.005	0.36	0.99
	PAD	0.16	0.35	0.64
	VTE	-12.01	744.56	0.99
	LV dysfunction	-13.03	789.73	0.99
	HT	-0.8	0.31	0.01
	DM	-0.55	0.59	0.35
	DLp	-0.23	0.33	0.49
	Genetic and others	0.57	0.62	0.35
	Smoking	-0.64	0.31	0.04
	Alcohol	-0.68	0.34	0.04
	post-AVR	1.02	0.59	0.09
	post-MVR	0		
	CABG	-12.01	627.8	0.98
	Intervention to aortic aneurysm and/or dissection	0.27	0.47	0.57
Complication				
	Major bleeding	1.52	0.32	<0.01
	Infarction by aortic dissection	1.54	0.27	<0.01
	Paroxymal A Fib	-1.66	0.52	<0.01
Medication on admission				
	RAAS inhibitor	-0.06	0.31	0.85
	CCB	0.36	0.29	0.22
	β -blocker	0.04	0.39	0.93
	diuretics	0.6	0.44	0.17
	α -blocker	1.2	0.52	0.02
	warfarin	0.16	0.53	0.77

DOAC	-13.03	787.37	0.99
aspirin	0.8	0.41	0.05
clopidogrel	-14.17	771.42	0.99
cilostazol	-13.03	673.45	0.98
prasugrel	0	.	.
other anti-platelet drug	1.18	1.01	0.24
Anti-coagulant (warfarin or DOAC)	-0.33	0.52	0.52
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-0.02	0.38	0.96
Both anti-coagulant and anti-platelet	0.55	0.72	0.44
Anti-coagulant or anti-platelet	-0.26	0.34	0.45

SE; standard error, HR, hazard ratio, BP; blood pressure, eGFR; estimated glomerular filtration rate, A Fib; atrial fibrillation, CAD; coronary artery diseases, CVD; cardiovascular diseases, PAD; peripheral arterial diseases, VTE; venous thromboembolism, LV; left ventricular, HT; hypertension, DM; diabetes mellitus, DLp: dyslipidemia, AVR; aortic valve replacement, MVR; mitral valve replacement, CABG; coronary artery bypass grafting, RAAS; renin-angiotensin-aldosterone system, CCB; calcium channel blocker, DOAC; direct oral anti-coagulant.

Genetic and others includes Marfan syndrome, Loeys-Dietz syndrome, and Behçet's disease.

217

218 After adjustment for age and sex, systolic blood pressure, eGFR, history of
 219 hypertension, smoking habit, alcohol intake, complication of surgical procedures, and use
 220 of α -blocker were significantly associated with all-cause death (**Table 4**). Also, the use
 221 of anti-thrombosis (warfarin, DOAC, aspirin, clopidogrel) was not the predictor of all
 222 cause death (**Table 4**).

223

224 **Table 4. Age and sex-adjusted Cox proportional hazard model in transferred acute**

225 **aortic dissection patients (type A)**

	β	SE	p-value
Systolic BP	-0.02	0.004	<0.01
Diastolic BP	-0.01	0.008	0.17
Heart rate	0.01	0.006	0.07
eGFR	-0.03	0.006	<0.01
Past history			
A Fib	-1.21	0.72	0.10
CAD	0.7	0.4	0.09
Other CVD	-0.08	0.37	0.83
PAD	0.05	0.36	0.89
VTE	-12.06	752.05	0.99
LV dysfunction	-12.99	788.9	0.99
HT	-0.88	0.32	<0.01
DM	-0.58	0.59	0.33
DLp	-0.2	0.34	0.56
Genetic and others	0.71	0.63	0.26
Smoking	-0.86	0.36	0.02
Alcohol	-0.8	0.38	0.03
post-AVR	1.01	0.61	0.10
post-MVR	0		
CABG	-12.24	633.99	0.98
Intervention to aortic aneurysm and/or dissection	0.18	0.49	0.72
Complication			
Major bleeding	1.48	0.32	<0.01
Infarction by aortic dissection	1.52	0.27	<0.01
Paroxymal A Fib	-1.75	0.52	<0.01

Medication on admission			
RAAS inhibitor	-0.14	0.31	0.66
CCB	0.29	0.29	0.33
β-blocker	-0.05	0.39	0.89
diuretics	0.48	0.44	0.27
α-blocker	1.16	0.52	0.03
warfarin	-0.002	0.54	0.99
DOAC	-13.24	796.32	0.99
aspirin	0.75	0.42	0.07
clopidogrel	-14.35	776.75	0.99
cilostazol	-13.12	675.96	0.98
prasugrel	0		
other anti-platelet drug	1.14	1.02	0.27
Anti-coagulant (warfarin or DOAC)	-0.48	0.53	0.36
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-0.11	0.38	0.78
Both anti-coagulant and anti-platelet	0.49	0.72	0.50
Anti-coagulant or anti-platelet	-0.41	0.36	0.25

226

227 **Cox proportional hazards regression analysis of all-cause death in TRANSFERRED**

228 **patients in type B**

229 In the Cox proportional hazards regression analysis of all-cause death, systolic blood

230 pressure, heart rate, eGFR, the history of atrial fibrillation, complication of surgical

231 procedures, and use of diuretics were significantly associated with all-cause death (**Table**

232 **5**). Also in this analysis, the use of anti-thrombosis (warfarin, DOAC, aspirin,

233 clopidogrel) was not the predictor of all cause death (**Table 5**).

234

235 **Table 5. Cox proportional hazard model in transferred acute aortic dissection**

236 **patients (type B)**

	β	SE	p-value
Age	0.0005	0.02	0.98
Sex	-0.64	0.65	0.32
Systolic BP	-0.03	0.01	0.02
Diastolic BP	-0.02	0.02	0.24
Heart rate	0.03	0.01	0.04
eGFR	-0.02	0.01	0.04
Past history			
A Fib	1.93	0.67	<0.01
CAD	-14.08	1484	0.99
Other CVD	0.18	0.77	0.81
PAD	0.47	0.6	0.43
VTE	0	.	.
LV dysfunction	0	.	.
HT	14.09	1400	0.99
DM	0.12	0.77	0.87
DLp	-0.04	0.66	0.95
Genetic and others	-14.07	1509	0.99
Smoking	0.21	0.6	0.72
Alcohol	-0.2	0.57	0.73
post-AVR	-14.09	1577	0.99
post-MVR	-11.01	1501	0.99
CABG	-12.01	1543	0.99
Intervention to aortic aneurysm and/or dissection	-0.45	1.04	0.67

Complication			
Major bleeding	3.87	0.59	<0.01
Infarction by aortic dissection	2.04	0.57	<0.01
Paroxymal A Fib	-14.09	1435	0.99
Medication on admission			
RAAS inhibitor	-16.67	1711	0.99
CCB	0.14	0.61	0.82
β-blocker	-0.2	0.78	0.80
diuretics	1.9	0.79	0.02
α-blocker	-14.05	1838	0.99
warfarin	0.4	1.06	0.71
DOAC	-13.02	2047	0.99
aspirin	-15.16	1903	0.99
clopidogrel	-13.04	2043	0.99
cilostazol	-13.05	1571	0.99
prasugrel	0		
other anti-platelet drug	-12.01	2086	0.99
Anti-coagulant (warfarin or DOAC)	-0.12	1.04	0.91
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-15.19	1457	0.99
Both anti-coagulant and anti-platelet	-13.03	1218	0.99
Anti-coagulant or anti-platelet	-1.02	1.04	0.33

237

238 After adjustment for age and sex, systolic blood pressure, heart rate, eGFR, the

239 history of atrial fibrillation, complication of surgical procedures, and use of diuretics were

240 significantly associated with all-cause death (**Table 6**), and the use of anti-thrombosis

241 was not the predictor of all cause death (**Table 6**).

242

243 **Table 6. Age and sex-adjusted Cox proportional hazard model in transferred acute**

244 **aortic dissection patients (type B)**

	β	SE	p-value
Systolic BP	-0.03	0.01	0.01
Diastolic BP	-0.02	0.02	0.18
Heart rate	0.03	0.02	0.05
eGFR	-0.02	0.01	0.02
Past history			
A Fib	2.05	0.69	<0.01
CAD	-14	1480	0.99
Other CVD	0.16	0.78	0.83
PAD	0.5	0.61	0.41
VTE	0	.	.
LV dysfunction	0	.	.
HT	14.07	1400	0.99
DM	0.17	0.77	0.82
DLp	-0.02	0.66	0.98
Genetic and others	-14.11	1513	0.99
Smoking	-0.01	0.7	0.99
Alcohol	-0.39	0.6	0.52
post-AVR	-14.02	1587	0.99
post-MVR	-11.13	1515	0.99
CABG	-12.16	1558	0.99
Intervention to aortic aneurysm and/or dissection	-0.41	1.05	0.70
Complication			
Major bleeding	4.24	0.71	<0.01
Infarction by aortic dissection	2.04	0.57	<0.01
Paroxymal A Fib	-13.95	1435	0.99

Medication on admission			
RAAS inhibitor	-16.6	1710	0.99
CCB	0.33	0.63	0.60
β -blocker	-0.05	0.78	0.94
diuretics	1.83	0.79	0.02
α -blocker	-13.97	1835	0.99
warfarin	0.7	1.07	0.51
DOAC	-13.25	2020	0.99
aspirin	-15.33	1875	0.99
clopidogrel	-13.26	2052	0.99
cilostazol	-13.68	1616	0.99
prasugrel	0		
other anti-platelet drug	-12.41	2152	0.99
Anti-coagulant (warfarin or DOAC)	0.05	1.05	0.96
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-15.19	1449	0.99
Both anti-coagulant and anti-platelet	-13.01	1217	0.99
Anti-coagulant or anti-platelet	-0.94	1.05	0.37

245

246 **Cox proportional hazards regression analysis of all-cause death in HOSPITALIZED**

247 **patients in type A**

248 In the analysis of all-cause death, systolic blood pressure, eGFR, complication of surgical

249 procedures, and use of α -blocker and anti-thrombosis drugs were significantly associated

250 with all-cause death (**Table 7**). The use of anti-thrombosis (warfarin, DOAC, aspirin,

251 clopidogrel) significantly reduced hazard ratio (**Table 7**).

252

253 **Table 7. Cox proportional hazard model in hospitalized acute aortic dissection**

254 **patients (type A)**

	β	SE	p-value
Age	0.006	0.01	0.65
Sex	-0.11	0.31	0.72
Systolic BP	-0.02	0.006	<0.01
Diastolic BP	-0.005	0.01	0.63
Heart rate	0.01	0.008	0.11
eGFR	-0.028	0.007	<0.01
Past history			
A Fib	-1.34	1.01	0.19
CAD	0.67	0.53	0.21
Other CVD	0.22	0.42	0.60
PAD	0.04	0.45	0.93
VTE	-12.01	915.23	0.99
LV dysfunction	-13.04	930.19	0.99
HT	-0.28	0.48	0.56
DM	-0.56	0.73	0.44
DLp	-0.23	0.42	0.58
Genetic and others	0.47	0.77	0.54
Smoking	-0.52	0.36	0.15
Alcohol	-0.52	0.38	0.18
post-AVR	1.03	0.73	0.16
post-MVR	0		
CABG	-12.01	776.4	0.99
Intervention to aortic aneurysm and/or dissection	0.1	0.61	0.87
Complication			
Major bleeding	1.66	0.38	<0.01

Infarction by aortic dissection	1.63	0.33	<0.01
Paroxymal A Fib	-1.27	0.53	0.02
Medication on admission			
RAAS inhibitor	-0.073	0.38	0.85
CCB	0.54	0.35	0.12
β -blocker	-0.1	0.49	0.84
diuretics	0.58	0.54	0.28
α -blocker	1.32	0.61	0.03
warfarin	0.23	0.61	0.71
DOAC	-13.03	969.9	0.99
aspirin	0.61	0.54	0.26
clopidogrel	-14.21	884.34	0.99
cilostazol	-13.04	823.72	0.99
prasugrel	0		
other anti-platelet drug	1.69	1.02	0.10
Anti-thrombus during hospitalization			
Anti-coagulant (warfarin or DOAC)	-1.62	0.6	<0.01
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-2.88	1.01	<0.01
Both anti-coagulant and anti-platelet	-15.2	860.56	0.99
Anti-coagulant or anti-platelet	-2.12	0.53	<0.01

255

256 After adjustment for age and sex, systolic blood pressure, eGFR, complication
257 of surgical procedures, and use of α -blocker were significantly associated with all-cause
258 death (**Table 8**). Also in this analysis, the use of anti-thrombosis was also the significant
259 and strong predictor of reduced all cause death (**Table 8**).

260

261 **Table 8. Age and sex-adjusted Cox proportional hazard model in hospitalized acute**

262 **aortic dissection patients (type A)**

	β	SE	p-value
Systolic BP	-0.02	0.006	<0.01
Diastolic BP	-0.005	0.01	0.61
Heart rate	0.012	0.008	0.12
eGFR	-0.028	0.007	<0.01
Past history			
A Fib	-1.48	1.02	0.15
CAD	0.63	0.53	0.23
Other CVD	0.17	0.42	0.69
PAD	-0.04	0.46	0.93
VTE	-12.04	919.33	0.99
LV dysfunction	-13.02	930.55	0.99
HT	-0.33	0.48	0.50
DM	-0.58	0.73	0.42
DLp	-0.2	0.42	0.63
Genetic and others	0.58	0.78	0.46
Smoking	-0.78	0.42	0.06
Alcohol	-0.65	0.43	0.13
post-AVR	1.004	0.75	0.18
post-MVR	0		
CABG	-12.14	778.45	0.99
Intervention to aortic aneurysm and/or dissection	0.019	0.63	0.98
Complication			
Major bleeding	1.62	0.39	<0.01
Infarction by aortic dissection	1.64	0.33	<0.01
Paroxymal A Fib	-1.34	0.53	0.01

Medication on admission			
RAAS inhibitor	-0.11	0.38	0.77
CCB	0.52	0.36	0.14
β-blocker	-0.15	0.49	0.76
diuretics	0.52	0.54	0.34
α-blocker	1.31	0.61	0.03
warfarin	0.14	0.63	0.83
DOAC	-13.12	972.53	0.99
aspirin	0.55	0.55	0.31
clopidogrel	-14.39	881.58	0.99
cilostazol	-13.05	824.28	0.99
prasugrel	0		
other anti-platelet drug	1.62	1.03	0.12
Anti-thrombus during hospitalization			
Anti-coagulant (warfarin or DOAC)	-1.64	0.6	<0.01
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-2.9	1.01	<0.01
Both anti-coagulant and anti-platelet	-15.19	859.87	0.99
Anti-coagulant or anti-platelet	-2.17	0.53	<0.01

263

264 **Cox proportional hazards regression analysis of all-cause death in HOSPITALIZED**

265 **patients in type B**

266 In the analysis of all-cause death, heart rate, history of atrial fibrillation and complication

267 of surgical procedures were significantly associated with all-cause death (**Table 9**). In

268 this analysis, the use of anti-thrombosis was not the predictor of all cause death predictor

269 of all cause death (**Table 9**).

270

271 **Table 9. Cox proportional hazard model in hospitalized acute aortic dissection**

272 **patients (type B)**

	β	SE	p-value
Age	0.004	0.025	0.88
Sex	-0.65	0.79	0.41
Systolic BP	-0.011	0.014	0.40
Diastolic BP	-0.002	0.018	0.90
Heart rate	0.033	0.016	0.04
eGFR	-0.022	0.012	0.08
Past history			
A Fib	1.79	0.8	0.03
CAD	-14.08	1721	0.99
Other CVD	-15.23	1650	0.99
PAD	0.44	0.69	0.53
VTE	0	.	.
LV dysfunction	0	.	.
HT	14.1	1594	0.99
DM	-0.38	1.06	0.72
DLp	-1.02	1.05	0.33
Genetic and others	-14.07	1681	0.99
Smoking	0.26	0.69	0.71
Alcohol	-0.15	0.65	0.82
post-AVR	-14.1	1749	0.99
post-MVR	-11.01	2104	0.99
CABG	-12.01	1962	0.99
Intervention to aortic aneurysm and/or dissection	-15.21	1776	0.99

Complication			
Major bleeding	3.82	0.68	<0.01
Infarction by aortic dissection	2.58	0.66	<0.01
Paroxymal A Fib	-14.1	1623	0.99
Medication on admission			
RAAS inhibitor	-16.67	1876	0.99
CCB	-0.014	0.69	0.98
β -blocker	-0.81	1.06	0.44
diuretics	-14.05	2135	0.99
α -blocker	-14.05	2021	0.99
warfarin	-15.13	2435	0.99
DOAC	-13.02	2372	0.99
aspirin	-15.17	2114	0.99
clopidogrel	-12.03	1628	0.99
cilostazol	-13.06	1757	0.99
prasugrel	0		
other anti-platelet drug	-12.01	2395	0.99
Anti-thrombus during hospitalization			
Anti-coagulant (warfarin or DOAC)	-15.13	2087	0.99
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-0.38	1.06	0.72
Both anti-coagulant and anti-platelet	-12.01	1770	0.99
Anti-coagulant or anti-platelet	-0.91	1.06	0.39

273

274 After adjustment for age and sex, history of atrial fibrillation and complication
 275 of surgical procedures were significantly associated with all-cause death (**Table 10**). Also,
 276 the use of anti-thrombosis was not the predictor of all cause death predictor of all cause

277 death (Table 10).

278

279 **Table 10. Age and sex-adjusted Cox proportional hazard model in hospitalized acute**

280 **aortic dissection patients (type B)**

	β	SE	p-value
Systolic BP	-0.012	0.014	0.37
Diastolic BP	-0.005	0.019	0.79
Heart rate	0.035	0.018	0.05
eGFR	-0.025	0.013	0.05
Past history			
A Fib	1.87	0.83	0.02
CAD	-13.99	1722	0.99
Other CVD	-15.32	1649	0.99
PAD	0.44	0.71	0.53
VTE	0	.	.
LV dysfunction	0	.	.
HT	14.09	1589	0.99
DM	-0.32	1.06	0.76
DLp	-1	1.06	0.34
Genetic and others	-13.84	1682	0.99
Smoking	-0.099	0.8	0.90
Alcohol	-0.42	0.68	0.54
post-AVR	-13.79	1754	0.99
post-MVR	-11.24	2140	0.99
CABG	-12.21	1995	0.99
Intervention to aortic aneurysm and/or dissection	-15.16	1769	0.99
Complication			
Major bleeding	4.17	0.81	<0.01

Infarction by aortic dissection	2.6	0.66	<0.01
Paroxymal A Fib	-13.95	1622	0.99
Medication on admission			
RAAS inhibitor	-16.64	1879	0.99
CCB	0.14	0.71	0.85
β -blocker	-0.7	1.02	0.51
diuretics	-14.13	2151	0.99
α -blocker	-13.99	2021	0.99
warfarin	-14.86	2386	0.99
DOAC	-13.32	2347	0.99
aspirin	-15.46	2096	0.99
clopidogrel	-12.25	1637	0.99
cilostazol	-13.7	1797	0.99
prasugrel	0		
other anti-platelet drug	-12.37	2454	0.99
Anti-thrombus during hospitalization			
Anti-coagulant (warfarin or DOAC)	-15.03	2073	0.99
Anti-platelet drug (aspirin, clopidogrel, cilostazol, or prasugrel)	-0.31	1.08	0.78
Both anti-coagulant and anti-platelet	-12.29	1802	0.99
Anti-coagulant or anti-platelet	-0.82	1.08	0.44

282

Discussion

283

284 This is the first report to demonstrate that anti-thrombotic drugs did not worsen the
285 prognosis in patients with acute aortic dissection, in whom higher prevalence of previous
286 history of atrial fibrillation and cardiovascular diseases were observed. Although there
287 might be some hidden better conditions, the use of anti-thrombotic drugs during
288 hospitalization showed significantly better prognosis in type A, which was observed even
289 after adjustment for age and sex. Probably because more attention is paid in surgical repair
290 in patients with anti-thrombotic drugs, anti-thrombotic drugs did not worsen the prognosis
291 in acute aortic dissection. It is unknown if anti-thrombotic drugs have pharmacologically
292 beneficial effects in the clinical course of acute aortic dissection.

293

294 **Thrombus in False Lumen in Acute Aortic Dissection**

295 After aortic dissection development, thrombus is often created in false lumen. It has been
296 reported that the false lumen status is associated with poor outcomes[12]. The meta-
297 analysis indicated that partial thrombosis in false lumen is independently associated with
298 poor long-term survival in acute aortic dissection, compared with complete thrombosis
299 or patent false lumen[12]. Although the underlying mechanisms involved in the

300 association between false lumen status and outcomes are not fully elucidated, complete
301 thrombus formation of the false lumen has been considered to be a prerequisite for healing
302 the aorta[12]. Also, complete thrombus may be able to relieve pressure from the tear;
303 however, it may cause organ ischemia. In partial thrombosis in false lumen, organ
304 ischemia may occur, and further, thrombus and platelets can modulate inflammatory
305 reactions and immune responses. [13] [14] Although it remains unknown how anti-
306 thrombotic drugs work on the thrombus formation in false lumen, the present study
307 indicated that anti-thrombotic drugs did not worsen the prognosis in patients with acute
308 aortic dissection. The mechanisms how anti-thrombotic drugs work in acute aortic
309 dissection should be clarified in near future.

310

311 **Initial Medical Therapy in Acute Aortic Dissection**

312 Initial medical therapy should stabilize patients, control pain, and lower blood pressure
313 to prevent further propagation of the dissection and to lessen the risk of aortic rupture.[9]
314 The present study demonstrated that anti-thrombotic drugs do not worsen the prognosis;
315 however, it is not recommended to newly introduce anti-thrombotic drugs before transfer
316 of patients to comprehensive aortic centers or appropriate surgical consultation.[9]

317

318 **Medical Management during Hospitalization**

319 Blood pressure management is the most important.[9] β -Adrenergic blockade reduces not
320 only heart rate and blood pressure, but also provides anti-impulse therapy to decrease
321 aortic wall stress.[15] Besides appropriate blood pressure management, other therapeutic
322 medical strategies are required. Although the present study demonstrated that the
323 prognosis was comparable between with and without anti-thrombotic drugs during
324 hospitalization in type B aortic dissection, anti-thrombotic drug group showed
325 significantly better prognosis in patients with type A aortic dissection, suggesting that
326 anti-thrombotic drugs might be a new therapeutic strategy in type A. On the other hand,
327 anti-thrombotic drugs might not have been administered in poor condition, even if they
328 were indicated. In the present study, we were not able to exclude confounding by
329 indication.

330

331 **Long-term Medical Management**

332 Survival rate has been reported between 52% and 94% at 1 year and between 45% and
333 88% at 5 years in type A,[16] and between 56% and 92 % at 1 year and between 48% and
334 82% at 5 years in type B.[17] Long-term management of acute aortic dissection should
335 be performed to prevent late phase complications, including aneurysmal enlargement and

336 aortic rupture. Poorly controlled hypertension has been reported to increase late morbidity
337 and mortality.[18, 19] Thus, it is required to perform blood pressure control, screening
338 the patient and relatives for heritable disorders associated with aortic dissection, serial
339 imaging of the aorta, lifestyle modifications, and education.[16, 20] It should be clarified
340 if anti-thrombotic drugs improve in these patients in near future.

341

342 **Limitations**

343 The present study has several limitations. First, the present study was an observational
344 retrospective cohort study from a single center. Anti-thrombotic drugs were not
345 administered for aortic dissection, but for other cardiovascular diseases, such as coronary
346 artery diseases or atrial fibrillation. Second, the enrolled patients in the present study were
347 hospitalized in University Hospital. These patients might be in more severe condition.
348 Third, this study was not able to include the hidden severity data of acute aortic dissection
349 except the obtained medical records in the present study, which may affect the prognosis.
350 Fourth, confounding by indication cannot be excluded in anti-thrombotic drugs use in
351 hospitalized patients with type A aortic dissection. Fifth, we have no available data of
352 long-term prognosis.

353

354 **Conclusion**

355 We demonstrated that anti-thrombotic drugs did not worsen the prognosis in patients with
356 acute aortic dissection, indicating that we should not hesitate anti-thrombotic drugs if
357 indicated.

358

359 **Acknowledgements**

360 None

361

362 **Sources of Funding**

363 None.

364

365 **Disclosures**

366 The authors declare no conflict of interest.

367

368

369

References

370

371 1. Goebel N, Nagib R, Salehi-Gilani S, Ahad S, Albert M, Ursulescu A, et al. One-
372 stage hybrid aortic repair using the frozen elephant trunk in acute DeBakey type I aortic
373 dissection. *J Thorac Dis.* 2018;10:4195-203.

374 2. Shimamoto T, Komiya T, Tsuneyoshi H. Fate of uncomplicated acute type B
375 aortic dissection and impact of concurrent aortic dilatation on remote aortic events. *J*
376 *Thorac Cardiovasc Surg.* 2019;157:854-863.

377 3. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and
378 management: Part I: from etiology to diagnostic strategies. *Circulation.* 2003;108:628-
379 35.

380 4. Hirst AE, Jr., Johns VJ, Jr., Kime SW, Jr. Dissecting aneurysm of the aorta: a
381 review of 505 cases. *Medicine (Baltimore).* 1958;37:217-279.

382 5. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. *J*
383 *Intensive Care.* 2018;6:15.

384 6. Kimura T, Shiraishi K, Furusho A, Ito S, Hirakata S, Nishida N, et al. Tenascin
385 C protects aorta from acute dissection in mice. *Sci Rep.* 2014;4:4051.

386 7. Tahara N, Hirakata S, Okabe K, Tahara A, Honda A, Igata S, et al. FDG-PET/CT

- 387 images during 5 years before acute aortic dissection. *Eur Heart J.* 2016;37:1933.
- 388 8. Ohno-Urabe S, Aoki H, Nishihara M, Furusho A, Hirakata S, Nishida N, et al.
389 Role of Macrophage Socs3 in the Pathogenesis of Aortic Dissection. *J Am Heart Assoc.*
390 2018;7:e007389.
- 391 9. Malaisrie SC, Szeto WY, Halas M, Girardi LN, Coselli JS, Sundt TM, 3rd, et al.
392 2021 The American Association for Thoracic Surgery expert consensus document:
393 Surgical treatment of acute type A aortic dissection. *J Thorac Cardiovasc Surg.*
394 2021;162:735-758 e2.
- 395 10. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S,
396 Standardization Committee of the International Society on T, Haemostasis. Definition of
397 major bleeding in clinical investigations of antihemostatic medicinal products in non-
398 surgical patients. *J Thromb Haemost.* 2005;3:692-694.
- 399 11. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised
400 equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis.*
401 2009;53:982-992.
- 402 12. Li D, Ye L, He Y, Cao X, Liu J, Zhong W, et al. False Lumen Status in Patients
403 With Acute Aortic Dissection: A Systematic Review and Meta-Analysis. *J Am Heart*
404 *Assoc.* 2016;5:e003172.

- 405 13. Aoki H, Majima R, Hashimoto Y, Hirakata S, Ohno-Urabe S. Ying and Yang of
406 Stat3 in pathogenesis of aortic dissection. *J Cardiol.* 2021;77:471-474.
- 407 14. Hamad MA, Krauel K, Schanze N, Gauchel N, Stachon P, Nuehrenberg T, et al.
408 Platelet Subtypes in Inflammatory Settings. *Front Cardiovasc Med.* 2022;9:823549.
- 409 15. Svensson LG, Crawford ES. Aortic dissection and aortic aneurysm surgery:
410 clinical observations, experimental investigations, and statistical analyses. Part I. *Curr*
411 *Probl Surg.* 1992;29:817-911.
- 412 16. Braverman AC. Acute aortic dissection: clinician update. *Circulation.*
413 2010;122:184-188.
- 414 17. Tsai TT, Fattori R, Trimarchi S, Isselbacher E, Myrmet T, Evangelista A, et al.
415 Long-term survival in patients presenting with type B acute aortic dissection: insights
416 from the International Registry of Acute Aortic Dissection. *Circulation.* 2006;114:2226-
417 2231.
- 418 18. Melby SJ, Zierer A, Damiano RJ, Jr., Moon MR. Importance of blood pressure
419 control after repair of acute type a aortic dissection: 25-year follow-up in 252 patients. *J*
420 *Clin Hypertens (Greenwich).* 2013;15:63-68.
- 421 19. Chan KK, Lai P, Wright JM. First-line beta-blockers versus other
422 antihypertensive medications for chronic type B aortic dissection. *Cochrane Database*

423 Syst Rev. 2014;:CD010426.

424 20. Chaddha A, Eagle KA, Braverman AC, Kline-Rogers E, Hirsch AT, Brook R, et

425 al. Exercise and Physical Activity for the Post-Aortic Dissection Patient: The Clinician's

426 Conundrum. Clin Cardiol. 2015;38:647-651.

427

428

429

430 **Figure legends**

431

432 **Figure 1. Enrollment of transferred patients with acute aortic dissection**

433 Among 685 transferred patients, 15% in 454 type A and 16% in 231 type B patients had
434 already taken anti-thrombotic drugs.

435

436 **Figure 2. Kapan-Meier curves of transferred patients with acute aortic dissection**

437 There were no significant differences in survival rate between with and without anti-
438 thrombotic drugs on admission in both type A (panel A) and B (panel B).

439

440 **Figure 3. Enrollment of hospitalized patients with acute aortic dissection**

441 Among 650 hospitalized patients, 43% in 424 type A and 19% in 225 type B patients
442 were treated by anti-thrombotic drugs during hospitalization.

443

444 **Figure 4. Kapan-Meier curves of hospitalized patients with acute aortic dissection**

445 Survival rate was significantly better in anti-thrombotic drug group than the other in type
446 A (panel A), while there was no significant difference between with and without anti-
447 thrombotic drugs during hospitalization in type B (panel B).

Figure 1




Figure 2




Figure 3




Figure 4

